- Home
- GSK
as of 11-06-2026 3:49pm EST
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
| Founded: | 1715 | Country: | United Kingdom |
| Employees: | N/A | City: | N/A |
| Market Cap: | 93.3B | IPO Year: | 2013 |
| Target Price: | $59.12 | AVG Volume (30 days): | 5.3M |
| Analyst Decision: | Hold | Number of Analysts: | 9 |
| Dividend Yield: | Dividend Payout Frequency: | N/A | |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $45.80 - $61.70 | Next Earning Date: | 10-28-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 3.59% | Revenue Growth (next year): | 4.24% |
| P/E Ratio: | 32.75 | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | +14.66% |
Compare GSK vs Leading Stocks
See how GSK stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "GSK GSK plc (Each representing two) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.